| Ten Years' Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics |
27 |
| The Developing Story of Predictive Biomarkers in Colorectal Cancer |
26 |
| Multiple Exon Skipping in the Duchenne Muscular Dystrophy Hot Spots: Prospects and Challenges |
16 |
| Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants |
16 |
| Physician-Reported Benefits and Barriers to Clinical Implementation of Genomic Medicine: A Multi-Site IGNITE-Network Survey |
15 |
| The Role of Next-Generation Sequencing in Precision Medicine: A Review of Outcomes in Oncology |
15 |
| Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches |
15 |
| Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine |
14 |
| Pharmacogenomics of CYP2C9: Functional and Clinical Considerations |
12 |
| Feasibility of a Comprehensive Home Monitoring Program for Sarcoidosis |
10 |
| Applications of CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy |
9 |
| Colorectal Cancer Biomarkers in the Era of Personalized Medicine |
9 |
| Mutation-Based Therapeutic Strategies for Duchenne Muscular Dystrophy: From Genetic Diagnosis to Therapy |
9 |
| A Perspective on Microneedle-Based Drug Delivery and Diagnostics in Paediatrics |
9 |
| Genetic Testing to Guide Risk-Stratified Screens for Breast Cancer |
8 |
| Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition |
8 |
| Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer |
8 |
| Ethical Considerations Related to Return of Results from Genomic Medicine Projects: The eMERGE Network (Phase III) Experience |
8 |
| Blockchains for Secure Digitized Medicine |
8 |
| Barriers and Facilitators to Genetic Testing for Familial Hypercholesterolemia in the United States: A Review |
8 |
| A Metabolomics Approach to Pharmacotherapy Personalization |
7 |
| Pharmacogenomic Testing: Clinical Evidence and Implementation Challenges |
7 |
| The Emerging Role of Checkpoint Inhibition in Microsatellite Stable Colorectal Cancer |
7 |
| Primary Care Physicians' Knowledge, Attitudes, and Experience with Personal Genetic Testing |
6 |
| Evaluation of the Association of Omentin 1 rs2274907 A > T and rs2274908 G > A Gene Polymorphisms with Coronary Artery Disease in Indian Population: A Case Control Study |
6 |
| Polymer Therapeutics: Biomarkers and New Approaches for Personalized Cancer Treatment |
6 |
| A Genome-Wide Association Study of Idiopathic Dilated Cardiomyopathy in African Americans |
6 |
| Warfarin: The End or the End of One Size Fits All Therapy? |
6 |
| 40 Years of Percutaneous Coronary Intervention: History and Future Directions |
5 |
| The Impact of Potassium Channel Gene Polymorphisms on Antiepileptic Drug Responsiveness in Arab Patients with Epilepsy |
5 |
| Personalized Medicine and Molecular Interaction Networks in Amyotrophic Lateral Sclerosis (ALS): Current Knowledge |
5 |
| DPYD, TYMS and MTHFR Genes Polymorphism Frequencies in a Series of Turkish Colorectal Cancer Patients |
5 |
| Understanding Implementation Challenges to Genetic Testing for Familial Hypercholesterolemia in the United States |
5 |
| Metformin Pharmacogenetics: Effects of SLC22A SLC22A and SLC22A3 Polymorphisms on Glycemic Control and HbA1c Levels |
5 |
| Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis |
4 |
| The Effect of a Personalized Approach to Patient Education on Heart Failure Self-Management |
4 |
| Aligning the Aligners: Comparison of RNA Sequencing Data Alignment and Gene Expression Quantification Tools for Clinical Breast Cancer Research |
4 |
| Pharmacogenetic Tests in Reducing Accesses to Emergency Services and Days of Hospitalization in Bipolar Disorder: A 2-Year Mirror Analysis |
4 |
| Exploring Predictors of Genetic Counseling and Testing for Hereditary Breast and Ovarian Cancer: Findings from the 2015 U.S. National Health Interview Survey |
4 |
| Genetic Variations in Sweet Taste Receptor Gene Are Related to Chocolate Powder and Dietary Fiber Intake in Obese Children and Adolescents |
4 |
| P450 Pharmacogenetics in Indigenous North American Populations |
4 |
| Determination of Risk Factors for Venous Thromboembolism by an Adapted Caprini Scoring System in Surgical Patients |
4 |
| Perspective: Cellular and Molecular Profiling Technologies in Personalized Oncology |
4 |
| Access to Genetic Counselors in the Southern United States |
4 |
| Pharmacogenetics of Vascular Risk Factors in Alzheimer's Disease |
3 |
| Association of TLR4 Polymorphisms, Expression, and Vitamin D with Helicobacter pylori Infection |
3 |
| ATP-Binding Cassette Transporters in the Clinical Implementation of Pharmacogenetics |
3 |
| Direct-to-Consumer Genetic Testing Data Privacy: Key Concerns and Recommendations Based on Consumer Perspectives |
3 |
| Potential Impact of MicroRNA Gene Polymorphisms in the Pathogenesis of Diabetes and Atherosclerotic Cardiovascular Disease |
3 |
| Physician Experience with Direct-To-Consumer Genetic Testing in Kaiser Permanente |
3 |
